These results demonstrate that OLFML2B is a key mediator of CAF-driven tumor progression, underscoring its potential as a therapeutic target for disrupting CAF–cancer cell crosstalk in HCC. This evidence concerns the gene OLFML2B and hepatocellular carcinoma.